中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (4): 281-288.doi: 10.35541/cjd.20210833
中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组 中华医学会皮肤性病学分会儿童学组 中国老年保健医学研究会皮肤科分会
收稿日期:2021-11-16
修回日期:2022-01-24
发布日期:2022-04-01
通讯作者:
李邻峰；马琳
E-mail:zoonli@sina.com; bch_maleen@aliyun.com
Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine; Group on Children, Chinese Society of Dermatology; Committee on Dermatology, Chinese Association of Geriatric Research
Received:2021-11-16
Revised:2022-01-24
Published:2022-04-01
Contact:
Li Linfeng; Ma Lin
E-mail:zoonli@sina.com; bch_maleen@aliyun.com
摘要： 【摘要】 外用制剂是治疗特应性皮炎的主要手段，但目前国内对外用制剂的应用和患者指导尚存在一定的不足。中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组、中华医学会皮肤性病学分会儿童学组、中国老年保健医学研究会皮肤科分会的部分专家以国内外相关指南、共识和大量临床文献为基础，结合专家临床经验，制定特应性皮炎外用制剂的应用和患者指导共识，旨在规范特应性皮炎外用制剂的应用，提高疗效和安全性，减少和预防复发。
中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组 中华医学会皮肤性病学分会儿童学组 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022,55(4):281-288. doi:10.35541/cjd.20210833
Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology, Committee on Dermatology, Chinese Association of Geriatric Research. Expert consensus on rational application of topical agents and patient education for atopic dermatitis[J]. Chinese Journal of Dermatology, 2022, 55(4): 281-288.doi:10.35541/cjd.20210833
| ［1］ | Jung HJ, Bae JY, Kim JE, et al. Survey of disease awareness, treatment behavior and treatment satisfaction in patients with atopic dermatitis in Korea: a multicenter study ［J］. J Dermatol, 2018,45（10）:1172⁃1180. doi: 10.1111/1346⁃8138.14540. |
| ［2］ | Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review［J］. JAMA Dermatol, 2017,153（10）:1036⁃1042. doi: 10.1001/jamadermatol.2017.2437. |
| ［3］ | Li Y, Han T, Li W, et al. Awareness of and phobias about topical corticosteroids in parents of infants with eczema in Hangzhou, China［J］. Pediatr Dermatol, 2018,35（4）:463⁃467. doi: 10.1111/pde.13527. |
| ［4］ | Lee MK, Seo JH, Chu H, et al. Current status of patient education in the management of atopic dermatitis in Korea［J］. Yonsei Med J, 2019,60（7）:694⁃699. doi: 10.3349/ymj.2019.60. 7.694. |
| ［5］ | Barbarot S, Boralevi F, Shourick J, et al. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education［J］. J Eur Acad Dermatol Venereol, 2021,35（11）:2263⁃2269. doi: 10.1111/jdv.17526. |
| ［6］ | Liang Y, Tian J, Shen CP, et al. Therapeutic patient education in children with moderate to severe atopic dermatitis: a multicenter randomized controlled trial in China［J］. Pediatr Dermatol, 2018,35（1）:70⁃75. doi: 10.1111/pde.13362. |
| ［7］ | Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial［J］. J Allergy Clin Immunol, 2017,140（3）:845⁃853.e3. doi: 10.1016/j.jaci.2017.01. 029. |
| ［8］ | Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis［J］. J Allergy Clin Immunol, 2014,134（4）:824⁃830.e6. doi: 10.1016/j.jaci.2014.07.060. |
| ［9］ | Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection［J］. Skin Therapy Lett, 2005,10（5）:1⁃8. |
| ［10］ | Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies［J］. J Am Acad Dermatol, 2014,71（1）:116⁃132. doi: 10.1016/j.jaad. 2014.03.023. |
| ［11］ | Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2717⁃2744. doi: 10.1111/ jdv.16892. |
| ［12］ | Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020［J］. Allergol Int, 2020,69（3）:356⁃369. doi: 10. 1016/j.alit.2020.02.006. |
| ［13］ | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part I［J］. J Eur Acad Dermatol Venereol, 2018,32（5）:657⁃682. doi: 10.1111/jdv.14891. |
| ［14］ | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组. 规范外用糖皮质激素类药物专家共识［J］. 中华皮肤科杂志, 2015,48（2）:73⁃75. doi: 10.3760/cma.j.issn.0412⁃4030.2015.02.001. |
| ［15］ | 申春平, 王华, 王榴慧, 等. 地奈德乳膏与丁酸氢化可的松乳膏治疗婴幼儿特应性皮炎的多中心、随机、平行对照临床研究［J］. 中华皮肤科杂志, 2019,52（1）:11⁃15. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.003. |
| ［16］ | Chi CC, Wang SH, Wojnarowska F, et al. Safety of topical corticosteroids in pregnancy［J］. Cochrane Database Syst Rev, 2015,2015（10）:CD007346. doi: 10.1002/14651858.CD007346.pub3. |
| ［17］ | Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1644⁃1659. doi: 10.1111/jdv.15709. |
| ［18］ | Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children［J］. Br J Dermatol, 1998,138（2）:293⁃296. doi: 10.1046/j.1365⁃2133.1998.02077.x. |
| ［19］ | Warner MR, Camisa C. Topical corticosteroids［M］//Wolverton SE. Comprehensive dermatologic drug therapy. 3rd ed. New York: Saunders Elsvier, 2013:487⁃504. |
| ［20］ | Murphy VL, Patel DC, Lamb SR, et al. Topical corticosteroid allergy: results of sequential testing to a corticosteroid series in New Zealand［J］. Contact Dermatitis, 2021,85（1）:32⁃38. doi: 10.1111/cod.13776. |
| ［21］ | Keegel T, Saunders H, Milne R, et al. Topical corticosteroid allergy in an urban Australian centre［J］. Contact Dermatitis, 2004,50（1）:6⁃14. doi: 10.1111/j.0105⁃1873.2004.00275.x. |
| ［22］ | Liu L, Ong G. A randomized, open⁃label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis［J］. J Dermatolog Treat, 2018,29（5）:501⁃509. doi: 10.1080/09546634.2017.1401211. |
| ［23］ | Rubio⁃Gomis E, Martinez⁃Mir I, Morales⁃Olivas FJ, et al. Fluticasone in mild to moderate atopic dermatitis relapse: a randomized controlled trial［J］. Allergol Immunopathol （Madr）, 2018,46（4）:378⁃384. doi: 10.1016/j.aller.2017.12.001. |
| ［24］ | Faergemann J, Christensen O, Sjövall P, et al. An open study of efficacy and safety of long⁃term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2000,14（5）:393⁃396. doi: 10.1046/j.1468⁃3083.2000.00099.x. |
| ［25］ | Fukuie T, Hirakawa S, Narita M, et al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator⁃blinded, controlled study［J］. J Dermatol, 2016,43（11）:1283⁃1292. doi: 10.1111/1346⁃8138.13408. |
| ［26］ | Xu W, Li Y, Chen Z, et al. Wet⁃wrap therapy with halometasone cream for severe adult atopic dermatitis［J］. Postgrad Med, 2018,130（5）:470⁃476. doi: 10.1080/00325481.2018.1478108. |
| ［27］ | Chung JG, Cheng H, Croxson M, et al. Topical corticosteroid wet wrap treatment and adrenal suppression: an Auckland perspective［J］. JAAD Int, 2021,5:66⁃68. doi: 10.1016/j.jdin. 2021.08.002. |
| ［28］ | Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin［J］. Br J Dermatol, 2010,163（1）:70⁃77. doi: 10.1111/j.1365⁃2133.2010.09757.x. |
| ［29］ | Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5⁃year randomized trial［J］. Pediatrics, 2015,135（4）:597⁃606. doi: 10.1542/peds.2014⁃1990. |
| ［30］ | Mandelin JM, Rubins A, Remitz A, et al. Long⁃term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two⁃year open⁃label study［J］. Int J Dermatol, 2012,51（1）:104⁃110. doi: 10.1111/j.1365⁃4632.2011.05015.x. |
| ［31］ | 孔祥君, 卢桂玲, 聂振华. 0.1%他克莫司软膏外用致Kaposi水痘样疹1例［J］. 中国麻风皮肤病杂志, 2014,30（1）:49⁃51. |
| ［32］ | Lerbaek A, Agner T. Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus［J］. Br J Dermatol, 2004,150（6）:1210⁃1211. doi: 10.1111/j.1365⁃2133.2004.06008.x. |
| ［33］ | Crawford KM, Bostrom P, Russ B, et al. Pimecrolimus⁃induced tinea incognito［J］. Skinmed, 2004,3（6）:352⁃353. doi: 10.1111/j.1540⁃9740.2004.03796.x. |
| ［34］ | Lam M, Zhu JW, Tadrous M, et al. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta⁃analysis ［J］. JAMA Dermatol, 2021,157（5）:549⁃558. doi: 10.1001/jamadermatol.2021.0345. |
| ［35］ | Reitamo S, Rustin M, Harper J, et al. A 4⁃year follow⁃up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients［J］. Br J Dermatol, 2008,159（4）:942⁃951. doi: 10.1111/j.1365⁃2133.2008.08747.x. |
| ［36］ | Paller AS, Fölster⁃Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis［J］. J Am Acad Dermatol, 2020,83（2）:375⁃381. doi: 10.1016/j.jaad.2020.03.075. |
| ［37］ | Thaci D, Chambers C, Sidhu M, et al. Twice⁃weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months［J］. J Eur Acad Dermatol Venereol, 2010,24（9）:1040⁃1046. doi: 10.1111/j.1468⁃3083.2010.03577.x. |
| ［38］ | Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment［J］. Allergy, 2008,63（6）:742⁃750. doi: 10.1111/j.1398⁃9995.2008. 01683.x. |
| ［39］ | Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild⁃to⁃moderate atopic dermatitis: a phase IV open⁃label study （CrisADe CARE 1）［J］. Am J Clin Dermatol, 2020,21（2）:275⁃284. doi: 10.1007/s40257⁃020⁃00510⁃6. |
| ［40］ | Callender VD, Alexis AF, Stein Gold LF, et al. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild⁃to⁃moderate atopic dermatitis across racial and ethnic groups［J］. Am J Clin Dermatol, 2019,20（5）:711⁃723. doi: 10.1007/s40257⁃019⁃00450⁃w. |
| ［41］ | Eichenfield LF, Call RS, Forsha DW, et al. Long⁃term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis［J］. J Am Acad Dermatol, 2017,77（4）:641⁃649.e5. doi: 10.1016/j.jaad.2017.06.010. |
| ［42］ | Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871. |
| ［43］ | Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021. 04.085. |
| ［44］ | Nakagawa H, Nemoto O, Igarashi A, et al. Long⁃term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis［J］. J Dermatol, 2020,47（2）:114⁃120. doi: 10.1111/1346⁃8138.15173. |
| ［45］ | Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and a subsequent open⁃label, long⁃term study［J］. J Am Acad Dermatol, 2021,85（4）:854⁃862. doi: 10.1016/j.jaad.2021.06.014. |
| ［46］ | Peppers J, Paller AS, Maeda⁃Chubachi T, et al. A phase 2, randomized dose⁃finding study of tapinarof （GSK2894512 cream） for the treatment of atopic dermatitis［J］. J Am Acad Dermatol, 2019,80（1）:89⁃98.e3. doi: 10.1016/j.jaad.2018.06. 047. |
| ［47］ | 陈旭, 鞠梅, 俞晨, 等. 复方多粘菌素B软膏联合地奈德乳膏治疗亚急性/慢性湿疹的多中心、随机、双盲、平行对照临床研究［J］. 中华皮肤科杂志, 2016,49（8）:541⁃546. doi: 10.3760/cma.j.issn.0412⁃4030.2016.08.004. |
| ［48］ | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组. 外用中成药治疗湿疹皮炎的专家共识（2014）［J］. 中华皮肤科杂志, 2014,47（6）:440⁃441. doi: 10.3760/cma.j.issn.0412⁃4030.2014.06.023. |
| ［49］ | Juntongjin P, Pongprasert R. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema［J］. Dermatol Ther, 2019,32（4）:e12956. doi: 10.1111/dth.12956. |
| [1] | 孙晓丽 李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451. |
| [2] | 申晨 陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445. |
| [3] | 覃诗纯 李梦杰 陆晓云 肖风丽. 特应性皮炎的转录组学研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 365-369. |
| [4] | 李巍 尹慧彬. 特应性皮炎的部位异质性[J]. 中华皮肤科杂志, 2022, 55(4): 349-352. |
| [5] | 李妍 李明 徐薇 李邻峰. 【开放获取】凯普斯泰冷敷凝胶治疗成人轻中度特应性皮炎的随机双盲对照研究[J]. 中华皮肤科杂志, 2022, 55(4): 345-348. |
| [6] | 何素玲 田歆 梁景耀 邵蕾 李俊龙 黄琼霄 刘玉梅 王建琴. 重度特应性皮炎患者急性期和缓解期皮肤微生态研究[J]. 中华皮肤科杂志, 2022, 55(4): 329-336. |
| [7] | 刘擘 宋晓婷 廖双璐 于淼 栾婷婷 李若瑜 赵作涛. 【开放获取】巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察[J]. 中华皮肤科杂志, 2022, 55(4): 304-307. |
| [8] | 田晶 梁源 申春平 赵牧童 汪洋 王珊 焦磊 马琳. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 299-303. |
| [9] | 刘擘 宋晓婷 李若瑜 赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298. |
| [10] | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组 中华医学会皮肤性病学分会儿童学组. 【开放获取】特应性皮炎湿包疗法临床应用专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 289-294. |
| [11] | 余愫 郁天泽 李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365. |
| [12] | 王傲 姚煦. 特应性皮炎瘙痒机制的研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 357-361. |
| [13] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
| [14] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [15] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）[J]. 中华皮肤科杂志, 2022, 55(1): 1-11. |
|
